mdlinx mdlinx
Gastroenterology Articles on MDLinx
Latest (31) Full Text Top Read since last login Article Summary

Review article: an analysis of the efficacy, perforation rates and methods used in pneumatic dilation for achalasia
Alimentary Pharmacology and Therapeutics, 08/19/2011  Review Article  Clinical Article

Katzka DA et al. – The response for a single dilation session was 66% at 1 year and 59, 53, 50 and 25% at 2, 3, 5 and 10 years respectively. Pneumatic dilation is safer than commonly thought and efficacious, although multiple dilations will be needed over a lifetime in most patients. Standardisation of the technique should be attempted.

Methods
  • Literature search for all studies, in which pneumatic dilation was performed for treatment of achalasia, was conducted. Studies, in which clear endpoints of efficacy of single dilation sessions over a period of years, were chosen.

Results
  • Response for a single dilation session was 66% at 1 year and 59, 53, 50 and 25% at 2, 3, 5 and 10 years respectively.
  • Use of a Rigiflex dilator and multiple dilations during the initial treatment improved efficacy.
  • Overall perforation rate was only 2% (24/1358) of which only 1% required surgery.
  • Use of multiple dilations led to increased perforation risk.
  • Method of dilation used with regard to balloon size, pressure used, dilation times and single or multiple dilations varied in almost every study.

Read this article in Alimentary Pharmacology and Therapeutics read MDLinx article: Review article: an analysis of the efficacy, perforation rates and methods used in pneumatic dilation for achalasia

<< Previous Article | Next Article >>
Showing Latest Articles
Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top 50 of 2011

1 Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate Helicobacter, April 6, 2012    Clinical Article

2 Adalimumab in steroid-dependent Crohns disease patients: Prognostic factors for clinical benefit Inflammatory Bowel Disease, April 17, 2012    Clinical Article

3 Serrated Polyp Detection Rate During Screening Colonoscopy Colorectal Disease, March 14, 2012

4 High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures Alimentary Pharmacology and Therapeutics, March 12, 2012    Clinical Article

5 Natalizumab for moderate to severe Crohns disease in clinical practice Inflammatory Bowel Disease, April 3, 2012    Clinical Article

6 Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease Inflammatory Bowel Disease, April 23, 2012    Clinical Article

7 Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals Gastroenterology, April 6, 2012

8 Randomized Comparison of Two Non-Bismuth-Containing Second-line Rescue Therapies for Helicobacter pylori Helicobacter, April 11, 2012    Clinical Article

9 Natalizumab for moderate to severe Crohns disease in clinical practice Inflammatory Bowel Disease, April 18, 2012    Clinical Article

10 Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains Helicobacter, April 13, 2012    Clinical Article

11 Scheduled infliximab monotherapy to prevent recurrence of Crohns disease following ileocolic or ileal resection: A 3-year prospective randomized open trial Inflammatory Bowel Disease, April 20, 2012    Clinical Article

12 Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease Inflammatory Bowel Disease, April 16, 2012    Clinical Article

13 Assessment of Helicobacter pylori Eradication by Virgin Olive Oil Helicobacter, April 24, 2012    Clinical Article

14 Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing Diseases of the Esophagus, April 27, 2012    Clinical Article

15 Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study Hepatology, April 19, 2012    Clinical Article

16 Systematic review: antibodies and anti-TNF- levels in inflammatory bowel disease Alimentary Pharmacology and Therapeutics, April 12, 2012    Clinical Article

17 Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis Journal of Digestive Diseases, March 27, 2012    Evidence Based Medicine    Clinical Article

18 Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial The Lancet Infectious Diseases, March 27, 2012    Clinical Article

19 The Association Between Barretts Esophagus and Helicobacter pylori Infection: A Meta-Analysis Helicobacter, April 3, 2012    Clinical Article

20 Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis Hepatology, April 6, 2012    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Edit My Newsletter Settings

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close